newsfilter
← Latest News
PR Newswire·

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company expects to announce topline data from its NIH sponsored Phase 2 clinical study during the fourth quarter of 2022 NEW YORK, July 20, 2022 /PRNewswire/